Miriam D. Post
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Miriam D. Post has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin G. Bitler
Department of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado
263 shared publications - Nicole Marjon
Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado
221 shared publications - Lindsay W. Brubaker
University of Colorado Denver 5 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Anschutz Medical Campus, Aurora, Colorado
189 shared publications - Elizabeth R. Woodruff
Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado
146 shared publications - Kimberly Jordan
Department of Immunology & Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
141 shared publications - Jennifer K. Richer
University of Colorado Anschutz Medical Campus 1 Department of Pathology Aurora, Colorado
117 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
Acidic pH induces resistance to olaparib
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
Acidic pH induces resistance to olaparib
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
P300 inhibition and PARPi inhibitors synergize in suppressing EOC growth in vivo
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
P300 inhibition and PARPi inhibitors synergize in suppressing EOC growth in vivo
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
Acidic pH upregulates DNA repair pathway and attenuates PARPi-induced PARP1 trapping
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
Acidic pH upregulates DNA repair pathway and attenuates PARPi-induced PARP1 trapping
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
P300 inhibition overcomes PARPi resistance induced by acidic pH
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
P300 inhibition overcomes PARPi resistance induced by acidic pH
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
ERK inhibition overcomes resistance to PARPi induced by acidic pH
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
ERK inhibition overcomes resistance to PARPi induced by acidic pH
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
P300 regulates BRCA1 and FEN1 expression
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
P300 regulates BRCA1 and FEN1 expression
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
Acidic pH enhances p300 and PARP1 interaction
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
Acidic pH enhances p300 and PARP1 interaction
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
Acidic pH induces PARP1 K505 acetylation by p300 to promote PARPi resistance
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
Acidic pH induces PARP1 K505 acetylation by p300 to promote PARPi resistance
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
PARP1 K505 acetylation regulates PARPi sensitivity
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
PARP1 K505 acetylation regulates PARPi sensitivity
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
BRCA status does not regulate PARP1 K505Ac
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Targeting p300 Reverses Acidic Microenvironment–Induced PARP Inhibitor Resistance
BRCA status does not regulate PARP1 K505Ac